Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Kinder, gentler procedure gives superior results for stem cell transplants

14.12.2004


An improved stem cell transplant regimen that is well-tolerated and has a high success rate has been developed by researchers at Washington University School of Medicine in St. Louis. The procedure holds promise for treatment of blood and bone marrow disorders, immune dysfunction and certain metabolic disorders.

Designed for transplants that replace a patient’s bone marrow with stem cells from donor marrow, peripheral blood or umbilical cord blood, the procedure allows early recovery of immune function, nearly eliminates transplant rejection, and decreases the incidence and severity of "graft vs. host disease," a common complication in transplants.

Termed a "reduced-intensity" protocol, in pediatric patients it may minimize damage to sensitive growing tissues like the brain and reproductive organs.



The pilot study of the procedure is reported in the journal Bone Marrow Transplantation. It is available through advance online publication on Dec. 13 and will appear in a future print issue.

The regimen was administered to 11 pediatric and 5 adult patients at St. Louis Children’s and Barnes-Jewish hospitals and the Children’s Hospital of New Orleans who had non-malignant bone marrow or metabolic disorders such as sickle cell anemia, thalassemia or Hurler’s syndrome. Symptoms and disease parameters stabilized or improved in all patients that underwent successful transplants.

In a successful stem cell transplant, the donor stem cells become permanently established, or engrafted, in the patient’s bone marrow and continually produce healthy blood cells. To prevent the host immune system from destroying the foreign stem cells, physicians administer a pretransplant immune suppressing treatment.

"We wanted an approach that would effectively knock out the patient’s immune system to let the transplanted cells engraft, but then allow immune function to recover quickly," says study leader Shalini Shenoy, M.D., assistant professor of pediatrics and faculty member of the Siteman Cancer Center.

A key innovation in this study changes the timing of administering a powerful pretransplant conditioning drug. The drug, Campath-1H, targets and destroys several vital immune system components. Previous studies used Campath-1H in higher doses and gave the drug at transplant time. With such dosing, Campath stayed in the body for up to 56 days after the transplant.

"We give a short, three-day, lower-dose treatment of Campath, three weeks in advance of transplant," Shenoy says. "As a result, we ensure that Campath levels are lower by the time of transplant to help establish donor cells and allow early recovery of immune function."

With standard transplant protocols, immune function may not fully recover for a year or more, and during this time, the patient is highly susceptible to life-threatening infections. In this study, the patients’ immune function showed significant recovery by six months, and no major infections were encountered after this period.

Fourteen of the 16 patients had successful bone marrow engraftment of the donor stem cells and only one experienced late graft rejection, an unusually high rate of success according to Shenoy. Furthermore, the grafts took hold quickly. Donor stem cells had established in the bone marrow completely at one month, contrasting with other reduced-intensity protocols where donor engraftment is gradual and often takes many months.

The protocol also reduced the incidence and severity of graft vs. host disease, which occurs when transplanted immune cells attack various cells in the body. For the majority of patients who experienced graft vs. host disease, the symptoms were limited to the skin and were controlled with treatments that were later successfully withdrawn.

To minimize damage to still-growing tissues such as the brain and reproductive organs in pediatric patients, the protocol uses smaller doses of standard conditioning chemotherapeutic agents.

"In the past, physicians had to accept the potential for brain damage or sterility in pediatric patients treated with chemotherapy," Shenoy says. "We’re trying to provide treatments that protect developing tissues. We’ve had our first pregnancy and normal delivery in one of our stem cell transplant patients, so we think the protocol offers some hope."

Next, Shenoy plans to evaluate whether changing parameters and further reducing chemotherapy doses would enhance the protocol’s effectiveness. She will also conduct studies targeted at sickle cell anemia and chronic myelogenous leukemia to explore the potential for successful transplants in children with these disorders.

Gwen Ericson | EurekAlert!
Further information:
http://www.wustl.edu

More articles from Life Sciences:

nachricht Symbiotic bacteria: from hitchhiker to beetle bodyguard
28.04.2017 | Johannes Gutenberg-Universität Mainz

nachricht Nose2Brain – Better Therapy for Multiple Sclerosis
28.04.2017 | Fraunhofer-Institut für Grenzflächen- und Bioverfahrenstechnik IGB

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Making lightweight construction suitable for series production

More and more automobile companies are focusing on body parts made of carbon fiber reinforced plastics (CFRP). However, manufacturing and repair costs must be further reduced in order to make CFRP more economical in use. Together with the Volkswagen AG and five other partners in the project HolQueSt 3D, the Laser Zentrum Hannover e.V. (LZH) has developed laser processes for the automatic trimming, drilling and repair of three-dimensional components.

Automated manufacturing processes are the basis for ultimately establishing the series production of CFRP components. In the project HolQueSt 3D, the LZH has...

Im Focus: Wonder material? Novel nanotube structure strengthens thin films for flexible electronics

Reflecting the structure of composites found in nature and the ancient world, researchers at the University of Illinois at Urbana-Champaign have synthesized thin carbon nanotube (CNT) textiles that exhibit both high electrical conductivity and a level of toughness that is about fifty times higher than copper films, currently used in electronics.

"The structural robustness of thin metal films has significant importance for the reliable operation of smart skin and flexible electronics including...

Im Focus: Deep inside Galaxy M87

The nearby, giant radio galaxy M87 hosts a supermassive black hole (BH) and is well-known for its bright jet dominating the spectrum over ten orders of magnitude in frequency. Due to its proximity, jet prominence, and the large black hole mass, M87 is the best laboratory for investigating the formation, acceleration, and collimation of relativistic jets. A research team led by Silke Britzen from the Max Planck Institute for Radio Astronomy in Bonn, Germany, has found strong indication for turbulent processes connecting the accretion disk and the jet of that galaxy providing insights into the longstanding problem of the origin of astrophysical jets.

Supermassive black holes form some of the most enigmatic phenomena in astrophysics. Their enormous energy output is supposed to be generated by the...

Im Focus: A Quantum Low Pass for Photons

Physicists in Garching observe novel quantum effect that limits the number of emitted photons.

The probability to find a certain number of photons inside a laser pulse usually corresponds to a classical distribution of independent events, the so-called...

Im Focus: Microprocessors based on a layer of just three atoms

Microprocessors based on atomically thin materials hold the promise of the evolution of traditional processors as well as new applications in the field of flexible electronics. Now, a TU Wien research team led by Thomas Müller has made a breakthrough in this field as part of an ongoing research project.

Two-dimensional materials, or 2D materials for short, are extremely versatile, although – or often more precisely because – they are made up of just one or a...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Fighting drug resistant tuberculosis – InfectoGnostics meets MYCO-NET² partners in Peru

28.04.2017 | Event News

Expert meeting “Health Business Connect” will connect international medical technology companies

20.04.2017 | Event News

Wenn der Computer das Gehirn austrickst

18.04.2017 | Event News

 
Latest News

Wireless power can drive tiny electronic devices in the GI tract

28.04.2017 | Medical Engineering

Ice cave in Transylvania yields window into region's past

28.04.2017 | Earth Sciences

Nose2Brain – Better Therapy for Multiple Sclerosis

28.04.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>